SCHEMBL6484576

SCHEMBL6484576

Cc1ccccc1OCCOc1ccc2c3c1c1c(n3CCC2)CCNCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.42
CYP2D6 P10635 2/20 0.41
CYP2C19 P33261 2/20 0.41
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 2/20 0.37
HTT P42858 1/20 0.37
HTR2C P28335 6/20 0.36
HTR2A P28223 4/20 0.35
HRH3 Q9Y5N1 1/20 0.35
MAPT P10636 3/20 0.34
HSD17B10 Q99714 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
POLB P06746 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
MCL1 Q07820 2/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
BCL2 P10415 1/20 0.34
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6492865 0.90 HTR2C (0.37) CYP2D6CYP2C19ALDH1A1HTR2CHTR2A
SCHEMBL6491392 0.89 TSHR (0.42) CYP2D6CYP2C19ALDH1A1HTTHTR2C
SCHEMBL6496852 0.88 KDM4E (0.37) TDP1CYP2D6CYP2C19ALDH1A1KDM4E
SCHEMBL6486177 0.88 HTR2C (0.41) TDP1CYP2D6CYP2C19ALDH1A1KDM4E
SCHEMBL6482544 0.86 MCL1 (0.47) TDP1CYP2D6CYP2C19KDM4EHTR2C
SCHEMBL6498263 0.86 KDM4E (0.42) TDP1ALDH1A1KDM4EHTTMAPT
SCHEMBL6492664 0.86 HRH3 (0.37) HTR2CHTR2AHRH3
SCHEMBL6486474 0.85 HTR2C (0.36) CYP2D6HTR2CHTR2AHRH3MCL1
SCHEMBL6481002 0.85 HTR2C (0.39) CYP2D6CYP2C19ALDH1A1HTR2CHTR2A
SCHEMBL6495903 0.84 KDM4E (0.41) TDP1CYP2C19ALDH1A1KDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050282796-A1 Tetracyclic azepinoindole compounds PFIZER 2005-12-22 US claimed
EP-1173440-B1 TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS UPJOHN CO (US) 2004-09-15 EP claimed
US-20020198190-A1 Tetracyclic azepinoindole compounds PHARMACIA & UPJOHN COMPANY 2002-12-26 US claimed
US-20050282796-A1 Tetracyclic azepinoindole compounds PFIZER 2005-12-22 US disclosed
US-6875762-B2 Tetracyclic azepinoindole compounds PFIZER (US) 2005-04-05 US disclosed
EP-1173440-B1 TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS UPJOHN CO (US) 2004-09-15 EP disclosed
US-20040138202-A1 Tetracyclic azepinoindole compounds PHARMACIA AND UPJOHN COMPANY 2004-07-15 US disclosed
US-20020198190-A1 Tetracyclic azepinoindole compounds PHARMACIA & UPJOHN COMPANY 2002-12-26 US disclosed
US-6407092-B1 5-HYDROXYTRYPTAMINE MODULATORS AND ANTISEROTONINE AGENTS; TREATING EATING, SEXUAL, SLEEP, NERVOUS SYSTEM, PSYCHOLOGICAL, AND GASTROINTESTINAL DISORDERS; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS PHARMACIA & UPJOHN COMPANY 2002-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282796-A1 Tetracyclic azepinoindole compounds TBXA2R, NPY5R, AZI2 TDP1 1839/4885CYP2D6 23/4885CYP2C19 12/4885
US-20040138202-A1 Tetracyclic azepinoindole compounds TPH1, AZI2, CYP1A2 TDP1 881/4885CYP2D6 23/4885CYP2C19 25/4885
US-20020198190-A1 Tetracyclic azepinoindole compounds TPH1, AZI2, CYP1A2 TDP1 881/4885CYP2D6 23/4885CYP2C19 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.